02086nam a2200277 4500 ESSALUD 20260903091623.0 ta t pe ||||| |||| 00| 0 spa d BMG eng Hwang, Thomas J. Autor 54498 Reforming payment for clinician-administered drugs — Most-favored-nation pricing in medicare Part B páginas: 1774-1777 Addressing escalating spending on prescription drugs by Medicare Part B, which covers clinician-administered drugs, has been a top U.S. policy priority. On December 19, 2025, the Trump administration announced a new payment model to align Medicare Part B fee-for-service payments for prescription drugs with international pricing benchmarks. This proposal — the Global Benchmark for Efficient Drug Pricing (GLOBE) model — was released alongside parallel most-favored-nation pricing models for Medicare Part D (Guarding U.S. Medicare against Rising Drug Costs, or GUARD) and Medicaid (Generating Cost Reductions for U.S. Medicaid, or GENEROUS). These announcements followed a May 2025 executive order calling for most-favored-nation pricing and previous efforts by the Obama administration and the first Trump administration to control Part B spending. If implemented, the GLOBE model could reduce costs for Medicare beneficiaries, taxpayers, and the Medicare program. But exceptions could limit participation in the model, and, in the absence of safeguards, its provisions could alter incentives for innovation. ALERGIA 7055 INMUNOLOGÍA GENERAL 53664 EFICACIA COMPARATIVA 54499 COSTO DE LA ATENCIÓN MÉDICA 54150 MEDICAMENTOS, DISPOSITIVOS Y LA FDA 54223 POLÍTICA SANITARIA INTERNACIONAL 54131 Clemans-Cope, Lisa 54500 Kesselheim, Aaron S. 54501 22717 22676 Massachusetts NEJM Group NEJM015 The New England Journal of Medicine ESSALUD 0028-4793 ARTICULOS 2026-08-31 sqb 22912 22912